Modulation of inflammatory response by pentoxifylline is independent of heme oxygenase-1 pathway

Journal of Physiology and Pharmacology

Volumn 60, Issue 2, 2009, Pages 3-12

  Taha, H ^a   Grochot Przeczek, A ^a   Was, H ^a   Kotlinowski, J ^a   Kozakowska, M ^a   Marek, A ^a   Skrzypek, K ^a   Lackowska, B ^b   Balcerczyk, A ^c   Mustafa, S ^d   Dulak, J ^a   Jozkowicz, Alicja ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cytokines; Endothelial cells; HO 1 knockout mice; Inflammation; Monocytes macrophages

Indexed keywords

HEME OXYGENASE 1; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTOXEMIA; ENZYME ACTIVITY; GENOTYPE; HEART; HUMAN; HUMAN CELL; INFLAMMATION; INTIMA; KIDNEY; LEUKOCYTE; LIVER; MONOCYTE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SKIN; SPLEEN;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENDOTOXEMIA; HEME OXYGENASE-1; HUMANS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 68049083596     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Solerte SB, Fioravanti M, Cerutti N et al. Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications. Acta Diabetol 1997; 34: 67-74. (Pubitemid 27434403)
2. Sliwa K, Woodiwiss A, Kone VE et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004; 109: 750-755. (Pubitemid 38222895)
3. Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4: 297-307. (Pubitemid 15181910)
4. Jull A, Waters J, Arroll B. Pentoxifylline for treatment of venous leg ulcers. Lancet 2002; 359: 1550-1554.
5. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-97. (Pubitemid 17092322)
6. Minhas BS, Ripps A. Methods for enhancement of sperm function. Front Biosci 1996; 1: 65-71.
7. Rieckmann P, Weber F, Gunther A et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996; 64: 193-200. (Pubitemid 26096431)
8. Martins AMC, Nobre ACL, Almeida AC et al. Thalidomide and pentoxifylline block the renal effects of supernatants of macrophages activated with Crotalus durissus cascavella venom. Braz J Med Biol Res 2004; 37: 1525-1530.
9. Lin HI, Chu SJ, Wang D, Feng NH. Pharmacological modulation of TNF production in macrophages. J Microbiol Immunol Infect 2004; 37: 8-15. (Pubitemid 38478608)
10. Tong Z, Chen B, Dai H, Bauer PC, Guzman J, Costable U. Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophages. Ann Allergy Asthma Immunol 2004; 92: 234-239. (Pubitemid 38233662)
11. Lundblad R, Ekstrom P, Giercksky KE. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 1995; 3: 210-215.
12. Tukov FF, Luyendyk JP, Ganey PE, Roth RA. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci 2007; 100: 267-280. (Pubitemid 47617823)
13. Bielekova B, Lincoln A, McFarland H, Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000; 164: 1117-1124. (Pubitemid 30043742)
14. Beshay E, Croze F, Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. Clin Immunol 2001; 98: 272-279. (Pubitemid 32150617)
15. Blaine TA, Pollice PF, Rosier RN, Reynolds PR, Puzas JE, O'Keefe RJ. Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. The role of cAMP-mediated signaling mechanisms. J Bone Joint Surg Am 1997; 79: 1519-1528.
16. Bhandari V. Developmental differences in the role of interleukins in hyperoxic lung injury in animal models. Front Biosci 2002; 7: 1624-1633.
17. Bhat VB, Madyastha KM. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem Biophys Res Commun 2001; 288: 1212-1217.
18. Coimbra R, Melbostad H, Loomis W, Tobar M, Hoyt DB. Phosphodiesterase inhibition decreases NFkB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia. J Trauma 2005; 59: 575-582. (Pubitemid 43014921)
19. Ji Q, Zhang L, Jia H, Xu J. Pentoxifylline inhibits endotoxin-induced NFkB activation and associated production of proinflammatory cytokines. Ann Clin Lab Sci 2004; 34: 427-436. (Pubitemid 40040965)
20. Oh GS, Pae HO, Moon MK et al. Pentoxifylline protects L929 fibroblasts from TNFα toxicity via the induction of heme oxygenase-1. Biochem Biophys Res Commun 2003; 302: 109-113.
21. Sarady JK, Otterbein SL, Liu F, Otterbein LE, Choi AM. Carbon monoxide modulates endotoxin-induced production of granulocyte macrophage colony-stimulating factor in macrophages. Am J Respir Cell Mol Biol 2002; 27: 739-745. (Pubitemid 35381183)
22. Song R, Ning W, Liu F et al. Regulation of IL-1β-induced GM-CSF production in human airway smooth muscle cells by carbon monoxide. Am J Physiol Lung Cell Mol Physiol 2003; 284: 50-56. (Pubitemid 35471257)
23. Bulger EM, Garcia I, Maier RV. Induction of hemeoxygenase 1 inhibits endothelial cell activation by endotoxin and oxidant stress. Surgery 2003; 134: 146-152. (Pubitemid 37070332)
24. Wagener, da Silva JL, Farley T. Differential effects of heme oxygenase isoforms on heme mediation of endothelial intracellular adhesion molecule 1 expression. J Pharmacol Exp Ther 1999; 291: 416-423.
25. Ishikawa K, Navab M, Leitinger N, Fogelman AM, Lusis AJ. Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL. J Clin Invest 1997; 100: 1209-1216. (Pubitemid 27386307)
26. Chen YH, Chau LY, Lin MW et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J 2004; 25: 39-47. (Pubitemid 38055591)
27. Schillinger M, Exner M, Minar E et al. Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. J Am Coll Cardiol 2004; 43: 950-957. (Pubitemid 38352971)
28. Schillinger M, Exner M, Mlekusch W et al. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb Res 2002; 106: 131-136. (Pubitemid 35245237)
29. Chen YH, Lin SJ, Lin MW et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002; 111: 1-8.
30. Jozkowicz A, Huk I, Nigisch A, Cisowski J, Weigel G, Dulak J. Prostaglandin-J2 upregulates expression of matrix metalloproteinase-1 independently of activation of peroxisome proliferator-activated receptor-γ. Acta Biochim Pol 2003; 50: 677-687. (Pubitemid 38623801)
31. Visner GA, Lu F, Zhou H, Liu J, Kazemfar K, Agarwal A. Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: implications in the antiproliferative response to rapamycin. Circulation 2003; 107: 911-916. (Pubitemid 36241052)
32. Rieder CRM, Williams AC, Ramsden DB. Selegiline increases heme oxygenase-1 expression and the cytotoxicity produced by dopamine treatment of neuroblastoma SK-N-SH cells. Braz J Med Biol Res 2004; 37: 1055-1062.
33. Deng YM, Ben JW, Witting PK, Stocker R. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation 2004; 110: 1855-1860. (Pubitemid 39299229)
34. Dulak J, Deshane J, Jozkowicz A, Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathology: focus on angiogenesis. Circulation 2008; 117: 231-241.
35. Szczepanik AM, Wordliczek J, Serednicki W, Siedlar M, Czupryna A. Pentoxifylline does not affect nociception if administered postoperatively. Pol J Pharmacol 2004; 56: 611-616. (Pubitemid 40123663)
36. Hill-Kapturczak N, Sikorski E, Voakes C, Garcia J, Nick HS, Agarwal A. An internal enhancer regulates heme- and cadmium-mediated induction of human heme oxygenase-1. Am J Physiol Renal Physiol 2004; 285: 515-523.
37. Zhang C, Li XY, Zhao L, Wang H, Xu DX. Lipopolysaccharide (LPS) up-regulates the expression of haem oxygenase-1 in mouse placenta. Placenta 2007; 28: 951-957. (Pubitemid 47074393)
38. Deree J, Martins J, de Campos T et al. Pentoxifylline attenuates lung injury and modulates transcription factor activity in hemorrhagic shock. J Surg Res 2007; 143: 99-108. (Pubitemid 47562450)
39. Deree J, de Campos T, Shenvi E, Loomis WH, Hoyt DB, Coimbra R. Hypertonic saline and pentoxifylline attenuates gut injury after hemorrhagic shock: the kinder, gentler resuscitation. J Trauma 2007; 62: 818-827. (Pubitemid 46624194)
40. Cerami A, Tracey KJ. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503. (Pubitemid 24985968)
41. Strieter RM, Remick DG, Ward PA et al. Cellular and molecular regulation of tumor necrosis factor-α production by pentoxifylline. Biochem Biophys Res Commun 1998; 155: 1230-1236.
42. van Leenen D, van der Poll T, Levi M et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993; 151: 2318-2325. (Pubitemid 23235705)
43. Bruynzeel I, van der Raaij LM, Willemze R, Stoof TJ. Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Arch Dermatol Res 1997; 289: 189-193. (Pubitemid 27170471)
44. Schonharting MM, Schade UF. The effect of pentoxifylline in septic shock - new pharmacologic aspects of an established drug. J Med 1989; 20: 97-105.
45. Wang W, Zolty E, Falk S, Basava V, Reznikov L, Schrier RW. Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol Renal Physiol 2006; 291: 1090-1095. (Pubitemid 44772043)
46. Michetti C, Coimbra R, Hoyt DB, Loomis W, Junger W, Wolf P. Pentoxifylline reduces acute lung injury in chronic endotoxemia. J Surg Res 2003; 115: 92-99. (Pubitemid 37323953)
47. Shirin H, Bruck R, Aeed H et al. Pentoxifylline prevents concanavalin A-induced hepatitis by reducing tumor necrosis factor-a levels and inhibiting adhesion of T lymphocytes to extracellular matrix. J Hepatol 1998; 29: 60-67. (Pubitemid 28307984)
48. Kwiecien S, Brzozowski T, Konturek PC, Pawlik MW, Kwiecien N, Konturek SJ. Gastroprotection by pentoxyfilline against stress-induced gastric damage. Role of lipid peroxidation, antioxidizing enzymes and proinflammatory cytokines. J Physiol Pharmacol 2004; 55: 337-355 (Pubitemid 38901967)
49. Kwiecien S, Pawlik MW, Sliwowski Z et al. Involvement of sensory afferent fibers and lipid peroxidation in the pathogenesis of stress-induced gastric mucosa damage. J Physiol Pharmacol 2007; 58: 149-162. (Pubitemid 47523112)
50. Hadjiminas DJ, McMasters KM, Robertson SE, Cheadle WG. Enhanced survival from cecal ligation and puncture with pentoxifylline is associated with altered neutrophil trafficking and reduced interleukin-1β expression but not inhibition of tumor necrosis factor synthesis. Surgery 1994; 116: 348-355.
51. Lenoble GM. New aspects of the pharmacology of pentoxifylline. J Mal Vasc 1989; 14: 35-41.
52. Fossat C, Sainty D, Stoppa AM, Maraninchi D, Vague J. Pentoxifylline in vitro reverses neutrophil chemotactic deficiency induced by interleukin-2 treatment. Nouv Rev Fr Hematol 1992; 34: 61-64. (Pubitemid 23274739)
53. Gebska A, Olszanecki R, Korbut R. Endotoxaemia in rats: role of leukocyte sequestration in rapid pulmonary nitric oxide synthase-2 expression. J Physiol Pharmacol 2005; 56: 299-311. (Pubitemid 40911095)
54. Deshane J, Chen S, Caballero S et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase-1 dependent mechanism. J Exp Med 2007; 204: 605-618. (Pubitemid 46457083)
55. Porter JM, Cutler BS, Lee BY et al. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled doubled-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104: 66-72.
56. Meininger V, Asselain B, Guillet P et al. Pentoxifylline in ALS. A doubled-blind, randomized, multicenter, placebo-controlled trial. Neurology 2006; 66: 88-92. (Pubitemid 43739598)
57. Zeni F, Pain P, Vindimian M et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996; 24: 207-214. (Pubitemid 26065326)
58. Staudinger T, Presterl E, Graninger W et al. Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Intensive Care Med 1996; 22: 888-893. (Pubitemid 26340635)
59. Farkas G, Nagy Z, Marton J, Mandi Y. Relevance of cytokine production to infected pancreatic necrosis. Acta Chir Hung 1997; 36: 86-88.
60. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 1998; 133: 94-100. (Pubitemid 28053174)
61. Lauterbach R, Zembala M. Pentoxifylline reduces plasma tumor necrosis factor-a concentration in premature infants with sepsis. Eur J Pediatr 1996; 155: 404-409. (Pubitemid 26117675)
62. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999; 27: 807-814. (Pubitemid 29218217)
63. Tsang GM, Allen S, Pagano D, Wong C, Graham TR, Bonser RS. Pentoxifylline preloading reduces endothelial injury and permeability in cardiopulmonary bypass. ASAIO J 1996; 42: 429-434. (Pubitemid 26363703)
64. Boldt J, Brosch C, Lehmann A, Haisch G, Lang J, Isgro F. Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients. Ann Thorac Surg 2001; 71: 1524-1529. (Pubitemid 32452538)
65. Cagli K, Ulas MM, Ozisik K et al. The intraoperative effect of pentoxifylline on the inflammatory process and leukocytes in cardiac surgery patients undergoing cardiopulmonary bypass. Perfusion 2005; 20: 45-51. (Pubitemid 40298235)
66. Wenisch C, Looareesuwan S, Wilairatana P et al. Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria. Am J Trop Med Hyg 1998; 58: 343-347. (Pubitemid 28160758)
67. Selim K, Huseyin C, Ibrahim KH, Hasan BU, Kazim U, Huseyin K. Effect of pentoxifylline on tumor necrosis factor-a and interleukin-6 levels in neonatal sepsis. Med J Malaysia 2004; 59: 391-394.
68. Hemmer CJ, Hort G, Chiwakata CB et al. Supportive pentoxifylline in falciparum malaria: no effect on tumor necrosis factor-α levels or clinical outcome: a prospective, randomized, placebo-controlled study. Am J Trop Med Hyg 1997; 56: 397-403.